




# KOSOVA JOURNAL OF SURGERY

## TRAUMA AND CRITICAL CARE SURGERY UPDATE: EXPANDING THE EVIDENCE — PART II



Milestones and Key Figures in the Development of Damage Control Surgery

- **VEDAT ELJEZI:** State of the Art Review: Extracorporeal Membrane Oxygenation (ECMO): A Life-Saving Therapy And Its Challenges of Implementation In Emerging Healthcare Systems
- **NOAH ANTES, HUNTER ROW, THOMAS HALDIS, CORNELIUS DYKE:** Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis: A Review and Special Considerations
- **LULEJETA ATLANTIDA LATIFI, RIFAT LATIFI:** Damage Control Surgery: An Update
- **WADE HOPPER, MENTOR AHMETI:** State of the Art Interventions in Geriatric Trauma
- **DANIEL SCHEESE, TRAVIS SULLIVAN, JEFFREY HAYNES, EDGAR RODAS:** Navigating the Challenges of Managing Pediatric Trauma: Current Trends, Evidence, and Practical Pathways
- **BELINDA DE SIMONE, FAUSTO CATENA, RIFAT LATIFI:** Venous Thromboembolism Prophylaxis in Trauma and Critically Ill Patients: A State-of-the-Art Evidence-Based Review
- **OLUWAFEMI P. OWODUNNI, ELLIOTT HAUT:** Implementing Sustainable Systems for Achieving Excellence in Venous Thromboembolism Prevention

**Volume 10, Issue 1, Part II:  
Trauma and Critical  
Care Surgery Update:  
Expanding the Evidence  
April 2026  
ISSN: 3027-5008 (Online)  
ISSN: 3027-5016 (Print)**



# Extracorporeal Membrane Oxygenation (ECMO): A Life-Saving Therapy and Its Challenges of Implementation In Emerging Healthcare Systems

VEDAT ELJEZI, MD, PHD

Pôle Médecine Péri-opératoire  
Centre Hospitalier Universitaire de Clermont-Ferrand,  
58 rue Montalembert, 63001 Clermont-Ferrand Cedex 1, France  
*E-mail:* veljezi@chu-clermontferrand.fr | *Tel:* +33 (0)4 73 75 15 90

## Abstract:

Extracorporeal membrane oxygenation (ECMO) is an advanced life support technology intended to treat critically ill patients with severe cardiac and/or respiratory failure not responding to standard treatment. By facilitating extra-corporeal gas exchange and circulatory support, ECMO allows recovery from injury and can serve as a transition to transplantation or long-term destination therapy. Since its inception during 1970s, ECMO's applications have expanded from a last-resort intervention to a standard advanced critical care, particularly in the situation of acute respiratory distress syndrome (ARDS), cardiogenic shock, and refractory cardiac arrest. Key studies, underline ECMO's role in improving survival rates in severe ARDS when applied in specialized centers. Despite its effectiveness, ECMO poses significant technical challenges, resource demands, and complications such as bleeding and infection. Moreover, the Covid-19 pandemic demonstrated the ECMO utility for critical care patients but also highlighted implementation difficulties in resource-limited settings. The technical functioning of ECMO involves veno-venous (VV-ECMO) only for respiratory support and veno-arterial (VA-ECMO) which supports both, the cardiac and respiratory needs. Contemporary systems utilize advanced materials and monitoring for improved patient outcomes. Addressing the logistical and financial barriers to ECMO integration into

healthcare systems is crucial for its sustainable and safe application globally.

**Keywords:** ECMO; extracorporeal membrane oxygenation; respiratory failure; cardiac support; ARDS; complications; critical care; healthcare challenges.

## Introduction: ECMO Definition and Significance

Extracorporeal membrane oxygenation (ECMO) is an effective temporary lifesaving technique<sup>1</sup>, intended to treat severely ill patients<sup>2</sup>. These patients have severe, yet potentially reversible, cardiac and/or respiratory failure and do not respond to conventional treatment<sup>1-3</sup>. ECMO offers gas exchange and hemodynamic support<sup>2</sup>, enables cardiac and pulmonary recovery from injury or pathologic process. It also serves as a transitory support to transplantation or long-term mechanical support in the patients with severe cardiac insufficiency<sup>4</sup>. ECMO was developed in the 1970s following pioneering work by Hill et al. and Bartlett et al<sup>5,6</sup>. Since then, considerable advances have been seen in both its technology and clinical applications and expanding indications. Previously considered “last resort therapy,” ECMO nowadays is recognized as a therapeutic option for certain patients. Rather than being considered an experimental rescue therapy, ECMO has become a core component of advanced critical care<sup>4,7</sup>. For the past twenty years, there has been increased evidence supporting ECMO usage

in ARDS, cardiogenic shock, refractory cardiac arrest, and septic shock both in adults and children. This evidence has come from large registries and randomized trials<sup>8</sup>. Improved survival in severe ARDS was demonstrated in the CESAR trial when patients were referred to ECMO centers<sup>9</sup>. The EOLIA trial confirmed these findings, showing that death rates in patients with severe ARDS may be reduced through early initiation of ECMO, despite the study's crossover limitations<sup>10</sup>. Similarly, registry-based analyses from the Extracorporeal Life Support Organization (ELSO) registry and multicenter trials have validated the benefit of VA-ECMO in severe cardiogenic shock and extracorporeal cardiopulmonary resuscitation (ECPR)<sup>11-13</sup>. Despite these advances, ECMO remains technically challenging and high resource-consuming. To optimize outcomes, specialized equipment, highly trained multidisciplinary teams, and careful patient selection are required<sup>8</sup>. Furthermore, this therapy carries several adverse events, including hemorrhage, thromboembolism, infection, vascular ischemic problems, neurological injury<sup>14</sup>. The worldwide growth of ECMO programs, particularly during the Covid-19 pandemic, highlights its pivotal role in advanced intensive care<sup>15</sup>. However, implementation remains challenging. This is especially true in resource-limited settings. Examples of these settings include countries currently developing ECMO capacity. The challenges arise due to financial, logistical, and training constraints<sup>16,17</sup>. It is crucial

to address these barriers to safely and sustainably integrate ECMO into national healthcare systems<sup>18</sup>.

### Technical Overview and Modes of ECMO

ECMO systems work by extracting deoxygenated blood through the venous circulation. The blood is subsequently oxygenated and decarboxylated via a membrane oxygenator before being returned to the circulatory system (2). Depending on the type of underlying pathology, there are two types of ECMO configurations: VV-ECMO and VA-ECMO<sup>4</sup>.

VV-ECMO provides respiratory support only and is indicated for patients with severe but potentially reversible respiratory failure and preserved cardiac function, such as those with ARDS<sup>19</sup>. The process involves extracting blood out of a major central vein (usually the femoral or internal jugular vein), oxygenating it outside the body (in an oxygenator), and reintroducing it into a central venous site<sup>2</sup> (Figure 1). This configuration facilitates efficient gas exchange while minimizing ventilator-induced lung injury, thereby promoting lung rest and recovery<sup>9</sup>. Multiple meta-analyses and registry data confirmed the beneficial role of ECMO in well-selected ARDS patients managed in experienced centers<sup>20-22</sup>.

In the other hand, VA-ECMO provides both cardiac and respiratory support, and is used for severe cardiogenic shock, cardiac arrest (ECPR), or combined cardiorespiratory




Fig.1: Veno-venous (V-V) ECMO




Fig.2: Veno-arterial (V-A) ECMO

failure<sup>11-13,15,23-25</sup>. The extraction of blood is initiated through a central vein access, most often the femoral vein or the right atrium. The extracted blood is then reintroduced into an artery, such as the femoral, subclavian, or carotid artery (Figure 2). This process effectively enables blood to bypass the native heart and lungs<sup>2,4</sup>. Peripheral VA-ECMO via femoral access is the most common approach, primarily due to its rapid bedside deployment, particularly in emergency or intensive care unit settings. The central cannulation procedure, in which direct access is provided to the right atrium and ascending aorta, is a specialized procedure reserved for post-cardiotomy patients or cases where peripheral access is contraindicated<sup>4,11</sup>.

Contemporary ECMO systems utilize biocompatible, heparin-coated circuits, centrifugal pumps, polymethylpentene-based oxygenators, and heat exchangers to ensure thermic stability and to limit hemolysis and thrombosis<sup>26</sup>. Portable ECMO devices, such as the CardioHelp™ and Rotaflow™ models, have facilitated secure inter-hospital transfers, thereby enabling the development of regionalized ECMO networks<sup>27</sup>. The necessity of continuous monitoring is imperative for the following parameters: circuit flow, pre- and post-oxygenator pressures, venous and arterial oxygen saturation, coagulation status, lactate levels, and echocardiographic parameters<sup>28</sup>. It is imperative to focus on left ventricular unloading during VA-ECMO, as retrograde arterial flow increases afterload, potentially resulting in ventricular distension and pulmonary congestion. This complication can be managed with inotropes, percutaneous ventricular assist devices (Impella®), or atrial septostomy<sup>29,30</sup>.

### Indications: Respiratory and Cardiac

The selection of appropriate patients is a fundamental aspect of effective ECMO therapy<sup>15,31-32</sup>. The decision to initiate ECMO is made with careful consideration of the potential for organ recovery in relation to the risks of associated complications<sup>1</sup>. The classification of indications is generally divided into two primary categories: respiratory (VV-ECMO) and cardiac (VA-ECMO)<sup>4</sup>. However, it is important to note that mixed or hybrid configurations may be employed in cases of combined heart-lung failure<sup>4</sup>.

VV-ECMO is used primarily for severely ill patients with potentially reversible respiratory failure who are unresponsive to optimal usual care<sup>31,33</sup>. This includes severe ARDS, air leak syndromes (e.g., bronchopleural fistula), near-fatal asthma, and massive pulmonary hemorrhage<sup>34-36</sup>. In addition to its primary function, ECMO can serve as a

transition to lung transplantation for patients with end-stage lung disease<sup>37</sup>. During the global coronavirus pandemic, VV-ECMO emerged as a critical therapeutic strategy for patients with refractory hypoxic respiratory failure<sup>21</sup>. A review of the extant literature, including data from the ELSO Registry and multicenter studies, suggests that the procedure is beneficial for carefully selected patients<sup>19,32</sup>. The mortality rate remains substantial, ranging from 37% to over 60%, depending on the presence of comorbidities and the duration of mechanical ventilation prior to ECMO<sup>38-39</sup>.

VA-ECMO is primarily employed in patients suffering from profound cardiogenic shock or during cardiac arrest, when myocardial recovery appears feasible, or as a temporary bridge to either heart transplantation or long-term mechanical circulatory support<sup>23-40</sup>. The main clinical situations in which VA-ECMO may be considered include: acute decompensation of chronic heart failure; cardiogenic shock secondary to acute coronary syndromes; fulminant myocarditis; low cardiac output syndrome following cardiac surgery; primary graft dysfunction occurring after heart transplantation; massive pulmonary embolism with circulatory collapse; refractory anaphylaxis or severe hypothermia complicated by cardiac arrest; drug-induced cardiac failure due to overdose of cardiotoxic agents; peripartum cardiomyopathy<sup>41</sup>. Extensive registry data and results from large multicenter cohorts demonstrate that VA-ECMO can offer a meaningful survival benefit in patients with otherwise unsurvivable cardiocirculatory failure<sup>15,32,42</sup>.

Extracorporeal cardiopulmonary resuscitation (ECPR) refers to the implementation of ECMO support during, or immediately following, conventional cardiopulmonary resuscitation (CPR) when spontaneous circulation has failed to be restored<sup>43</sup>. This strategy may result in a survival benefit, particularly in cases of witnessed cardiac arrest with minimal no-flow time and a potentially reversible underlying cause<sup>44</sup>. A comprehensive analysis of randomized clinical trials and observational registries has indicated that the efficacy of treatment outcomes is closely associated with the timely implementation of cannulation, the meticulous selection of candidates, and the presence of a highly skilled, multidisciplinary ECMO response team<sup>45</sup>.

### Contraindications and Ethical Considerations

The complexity of the procedure, the significant demands on resources, and the potential for severe complications necessitate its judicious application to patients with a reasonable probability of recovery<sup>46</sup>. In addition to identifying those who may benefit, it is also crucial to be able to

recognize individuals who are unlikely to have a positive outcome<sup>47</sup>. Contraindications to ECMO are generally categorized as absolute or relative, depending on the extent to which they preclude successful treatment<sup>48</sup>. Absolute contraindications include situations such as irreversible cardiac or pulmonary failure in the absence of a transplant option, disseminated malignancy, or severe permanent neurological damage<sup>49</sup>. ECMO is also contraindicated in patients with uncontrolled type A aortic dissection, severe aortic regurgitation, or those presenting with profound multiorgan failure following a prolonged low-flow state after cardiac arrest<sup>1,49</sup>. In addition, the presence of a valid do-not-resuscitate order or an advance directive declining life-sustaining treatment must be respected<sup>15,31,50</sup>. In contrast, relative contraindications require a case-by-case evaluation and depend on institutional experience and ethical considerations. These may include advanced age (typically above 75 years), morbid obesity (BMI > 40 kg/m<sup>2</sup>), significant peripheral vascular disease, active bleeding disorders or an inability to tolerate anticoagulation, and severely reduced functional status prior to the acute illness<sup>42,49</sup>. The ethical considerations associated with ECMO involve a range of complex issues, particularly in the context of end-of-life care and resource allocation<sup>41,47,51</sup>. Prolonged ECMO support in the absence of signs of recovery, particularly in settings with limited ICU capacity, can result in moral and societal dilemmas<sup>41</sup>. The utilization of ECMO should not be regarded exclusively as a technological intervention<sup>53</sup>. Its application requires a patient-centered, ethically justified medical decision<sup>41,46,51</sup>. This approach is founded on the integration of palliative care principles, when recovery is unfeasible<sup>52</sup>.

### Complications Associated with ECMO

ECMO is associated with a high incidence of serious and potentially fatal complications<sup>14,52</sup>. The causes of such complications include the extracorporeal circuit itself, the process of invasive cannulation, or the systemic effects of prolonged circulation and anticoagulation<sup>19,31,53</sup>. These complications depend on the type of the ECMO configuration (VA vs. VV), the underlying patient's pathology, the comorbidities, and the experience of the treating center<sup>54</sup>. Based on the results of a large multicenter study, 57% of patients reported at least one major ECMO related complication<sup>10</sup>. Vascular complications are among the most frequent and serious problems encountered during ECMO, especially when peripheral cannulation is used. Typical complications include arterial injury (e.g., dissection or

perforation), limb ischemia, bleeding events, and, in severe cases, compartment syndrome<sup>53,55</sup>. The femoral route, the most widely used access site, is also associated with the highest incidence of vascular injury. The central cannulation avoids peripheral ischemia but carries its own risks, including perforation of the right atrium and significant mediastinal bleeding<sup>40</sup>. Preventive measures, such as the use of distal perfusion catheters, continuous ultrasound doppler surveillance, and routine evaluation of distal limb perfusion, have significantly reduced ischemic complications<sup>56</sup>. Beyond vascular issues<sup>1</sup>, VA-ECMO with femoral access profoundly alters the patient's cardiovascular physiology. The retrograde flow generated by the arterial cannula increases left ventricular afterload, which can lead to distension, pulmonary congestion, and delayed myocardial recovery<sup>57</sup>. These effects are especially harmful in individuals with severely impaired ventricular function. To manage these hemodynamic disturbances, strategies focusing on left-sided heart decompression have been adopted. These strategies include pharmacological unloading through inotropes and vasodilators, mechanical approaches, such as percutaneous ventricular assist systems (e.g., Impella), or the creation of an atrial septostomy to facilitate decompression and prevent thrombus formation<sup>11,25,58</sup>.

When blood comes into contact with the synthetic surfaces of the extracorporeal circuit, it triggers a complex inflammatory and hemostatic response<sup>26</sup>. This response includes platelet activation, stimulation of the coagulation cascade, and secondary fibrinolytic disturbances, creating a complex balance between thrombosis and bleeding<sup>59</sup>. Thrombotic complications may develop within the ECMO system itself, such as oxygenator clot formation or circuit obstruction<sup>60</sup>. They may also manifest as systemic embolic events, including ischemic stroke<sup>61,62</sup>. On the other hand, hemorrhagic complications are among the most frequent and serious problems encountered during ECMO, affecting between 40% and 60% of adult recipients in large observational series<sup>60</sup>. Bleeding episodes may occur at cannulation or surgical insertion sites, in the gastrointestinal tract, or intracranially. The latter carries the most severe prognosis<sup>14,59,60</sup>. This dual risk is the result of multiple mechanisms. The continuous need for anticoagulation combined with thrombocytopenia, platelet dysfunction, hemodilution, and acquired von Willebrand factor abnormalities significantly increases the risk to bleeding<sup>60</sup>. Meticulous monitoring of coagulation markers, including activated clotting time, anti-Xa activity, platelet count, and fibrinogen concentration, is essential to reduce the occurrence

of such events<sup>63</sup>. Maintaining a safe therapeutic balance is crucial. Protocols based on the patient's evolving condition and supported by a multidisciplinary team experienced in hemostasis and critical care are essential<sup>64</sup>.

Neurological complications are among the most serious and prognostically significant adverse events in patients supported by ECMO<sup>61,62</sup>. A large proportion of morbidity and late disability among survivors is still attributed to cerebral injuries of various natures, including ischemic, hemorrhagic, and hypoxic<sup>65</sup>. According to data from major ECMO registries, acute brain insults, including stroke, seizure activity, prolonged coma, and diffuse hypoxic ischemic damage, are experienced by one in ten patients<sup>61</sup>. These events typically result from a combination of mechanisms, including the migration of thrombotic material, bleeding related to anticoagulation, and unstable cerebral perfusion due to rapid hemodynamic changes<sup>62</sup>. Neurological deterioration can develop insidiously, so continuous surveillance is crucial. The use of multimodal neuro-monitoring tools, particularly near-infrared spectroscopy (NIRS) to assess regional oxygenation, and periodic neuroimaging, when clinically feasible, can help identify early signs of compromise and guide timely intervention<sup>66</sup>.

Up to 85% of ECMO patients develop acute kidney injury (AKI), with approximately half requiring renal replacement therapy (RRT)<sup>67</sup>. The pathophysiology is characterized by a complex interaction of multiple mechanisms, involving hemodynamic instability, inflammatory response, hemolysis, and exposure to nephrotoxic substances<sup>67</sup>. AKI is strongly associated with increased mortality. It is also associated with prolonged ECMO duration<sup>14</sup>. Infections are another major source of morbidity, affecting over 50% of ECMO patients<sup>68-70</sup>. The most frequent infections include ventilator-associated pneumonia<sup>14,71</sup>, catheter-related bloodstream infections, and cannula-site infections<sup>70</sup>. Prolonged ECMO support, multiple invasive lines, and immunoparesis contribute to increased susceptibility<sup>69,72</sup>. To limit nosocomial infections, it is crucial to implement strict aseptic protocols, early source control, and antimicrobial stewardship<sup>68</sup>.

Harlequin syndrome, also known as north-south syndrome, is a unique phenomenon<sup>1,73</sup>. It may occur in VA-ECMO when native cardiac output recovers but remains poorly oxygenated. This leads to hypoxia in the upper body and brain<sup>73</sup>. Management involves increasing the FiO<sub>2</sub> on the ventilator, adjusting the ECMO flow rate, or converting to a hybrid configuration (V-AV ECMO), in order to optimize oxygen delivery<sup>1,11</sup>.

Even in experienced centers, ECMO complications remain common and can overcome its survival benefits<sup>74</sup>. To minimize adverse events, it is essential to strictly adhere to standardized protocols, continuously train staff, hold multidisciplinary rounds, and implement early detection systems<sup>18,75</sup>. ECMO complications highlight the importance of continuously reviewing the indications and benefits of the therapy<sup>74</sup>. The ECMO collaborative project can improve survival rates, the weaning rates, and reduce complications without increasing costs<sup>76</sup>.

### ECMO in Specific Clinical Scenarios

In addition to its traditional use in ARDS and cardiogenic shock, ECMO has shown its effectiveness in a variety of specific and serious medical situations<sup>4</sup>. These rare or complex scenarios frequently pose challenges to conventional management algorithms, but they highlight the adaptability and lifesaving potential of ECMO when used in suitable cases<sup>42,49</sup>.

Fulminant myocarditis is characterized by the rapid onset of heart failure and cardiogenic shock<sup>77</sup>. It frequently affects previously healthy young adults<sup>78</sup>. In this situation, VA-ECMO provides essential hemodynamic support while allowing the heart muscle to rest and recover<sup>77-79</sup>. Studies have shown survival rates of 60–70%, particularly when ECMO is initiated before the onset of multiorgan failure<sup>80-81</sup>. Early initiation of ECMO was strongly associated with improved outcomes in patients with fulminant myocarditis<sup>78</sup>. Following resolution of the inflammatory process, most patients can be successfully weaned from ECMO without experiencing any long-term complications<sup>77</sup>.

Peripartum cardiomyopathy (PPCM) is a rare, but potentially reversible, cause of acute heart failure happening during the last weeks of pregnancy or the first weeks after childbirth<sup>82</sup>. When conventional management fails, VA-ECMO can serve as a temporary circulatory bridge to either myocardial recovery or heart transplantation<sup>83,84</sup>. Recent studies report that 72% of patients were weaned off ECMO, with survival rates above 60% for well-selected patients<sup>85</sup>. Further research is needed to understand the long-term morbidity, functional status of peripartum ECMO survivors, and the potential impact of cardiopulmonary and psychosocial recovery programs<sup>83</sup>.

Another setting where ECMO provides a unique benefit is severe accidental hypothermia (core temperature <28°C), where this technology enables controlled rewarming and cardiopulmonary support<sup>86</sup>. Numerous case reports describe full neurological recovery, even after prolonged



cardiac arrest at extremely low core temperatures<sup>87</sup>. Ledoux and Saint-Léger published a case report describing the resuscitation of a 46-year-old patient with a core temperature of 22.4 °C<sup>88</sup>. The patient achieved full neurological recovery following VA-ECMO support. These cases have become the basis of the expression, “No one is dead until they’re warm and dead.”

In cases of acute, massive pulmonary embolism (PE) accompanied by hemodynamic collapse, VA-ECMO serves as a bridge to reperfusion therapy (89). It restores systemic oxygen delivery and stabilizes the patient for thrombolysis or surgical thrombectomy<sup>89,90</sup>. A multicenter study by Kjaergaard et al. found that 50% of 22 patients treated with ECMO for PE survived at one month, and 45% at one year<sup>34</sup>. Current evidence supports ECMO use in selected patients when prompt reperfusion therapy is expected to reverse the cause of failure<sup>91</sup>.

Overdoses with cardiotoxic drugs, such as beta-blockers, calcium channel blockers, and tricyclic antidepressants, can lead to refractory cardiac arrest or shock unresponsive to pharmacologic therapy<sup>92,93</sup>. ECMO can provide temporary circulatory and respiratory support in these cases until the drugs are eliminated from the body<sup>92,93</sup>. ECMO can be used to treat a variety of pharmacological and non-pharmacological exposures in both adults and pediatric patients. Survival rates were high when ECMO was administered prior to cardiac arrest<sup>94</sup>.

In cases of severe anaphylactic shock refractory to epinephrine and conventional resuscitation measures, VA-ECMO offers the potential to maintain perfusion while allowing for the resolution of the hypersensitivity response<sup>95</sup>. Despite the paucity of empirical evidence, the available case reports indicate that this application is consistent with the role of ECMO as a bridge to recovery in cases of cardiovascular collapse caused by reversible conditions<sup>95,96</sup>.

During the COVID-19 pandemic, VV-ECMO became a pivotal therapeutic intervention for patients with refractory hypoxemia secondary to severe viral ARDS. A comprehensive analysis of data from the ELSO registry and multiple cohort studies has confirmed survival rates of 40–50% in carefully selected patients<sup>21,22,97,98</sup>. The early referral to experienced ECMO centers and strict selection criteria emerged as critical determinants of success<sup>10,55</sup>. These findings further solidify the critical role of ECMO in the management of severe, reversible respiratory failure, even in the context of unprecedented global healthcare challenges.

ECMO may be considered for some cases of septic shock complicated by severe and unresponsive cardiac

and/or respiratory failure<sup>99</sup>. In this context, VA-ECMO can provide temporary circulatory support in patients with septic cardiomyopathy and severe myocardial depression that does not respond to maximum medical therapy<sup>100</sup>. However, its use remains controversial because ECMO does not treat the underlying infection and may exacerbate inflammatory and coagulation disturbances<sup>101</sup>. Therefore, careful patient selection is essential, observing the greatest benefit in younger patients with reversible myocardial dysfunction and limited comorbidities<sup>99-101</sup>.

These clinical scenarios illustrate the expanding role of ECMO beyond its traditional indications. The success of the intervention is determined by optimal timing of the intervention, the reversibility of the underlying disease, and the coordination of a multidisciplinary team. In carefully selected patients when ECMO is implemented early, survival rates may exceed 40-50% for conditions previously considered fatal<sup>55</sup>.

### Outcomes and Prognostic Data

The clinical benefits of ECMO extend beyond its immediate capacity to support organ failure. Its true value lies in improving survival, minimizing complications, and optimizing long-term functional recovery. The results obtained vary considerably based on the indication for the procedure, the timing of its initiation, the patient’s characteristics, and the experience of the medical center<sup>102</sup>. The ELSO registry constitutes the most extensive and comprehensive global database on the utilization and outcomes of ECMO. As stated in the 2023 ELSO International Report, the survival rate for VV-ECMO used in respiratory failure was approximately 58%, whereas VA-ECMO for cardiac support demonstrated survival rates between 44%<sup>8</sup>. For ECPR, survival remains lower, with an average of 25–30%<sup>8,103</sup>. However, significant variability exists depending on institutional experience and post-resuscitation care. More recent reports show incremental improvements, particularly in centers with high ECMO volumes and structured multidisciplinary teams<sup>104</sup>.

In patients with cardiogenic shock, VA-ECMO provides rapid hemodynamic stabilization and improves end-organ perfusion, resulting in better short-term survival (105). However, complication rates remain high, including bleeding, thromboembolism, and limb ischemia<sup>40,105</sup>. Other publications identified a pooled in-hospital mortality rate of 62%. Higher mortality was associated with patient age, infection, and duration of ECMO support<sup>52</sup>. Thirty percent of patients remain alive and free of disability at 12 months

after VA-ECMO initiation, with differences in outcomes associated with the reason for initiation. The majority of disability appears to develop within the first six months after VA-ECMO initiation and continues through the 12-month period<sup>106</sup>. Long-term outcomes are more favorable in reversible causes such as myocarditis or post-cardiotomy shock than in chronic heart failure<sup>107</sup>.

Two pivotal randomized trials, CESAR<sup>9</sup> and EOLIA<sup>10</sup>, established the contemporary function of ECMO in ARDS. The CESAR trial reported an improved survival rate without severe disability at six months among patients in the ECMO group compared to patients in the conventional ventilation group (63% vs. 47%;  $p = 0.03$ )<sup>9</sup>. The EOLIA trial found no statistically significant difference in 60-day mortality (35% in the ECMO group versus 46% in the control group;  $p = 0.09$ ). However, 28% crossover from the control group to the ECMO group likely diluted the observed benefit<sup>10</sup>. Additional meta-analyses and studies of individual patient data have confirmed a modest survival advantage associated with early VV-ECMO initiation in patients with severe, refractory hypoxemia<sup>20</sup>. In addition, ECMO patients experienced improved lung recovery and reduced ventilator-induced lung injury when treated at experienced centers<sup>27</sup>.

The use of ECMO during cardiac arrest, also known as ECPR, has increased in recent years. While survival remains relatively low, typically ranging from 20% to 30% for hospital discharge<sup>24,43</sup>, selected patients, particularly those with a witnessed arrest and a short low-flow time, can achieve favorable neurological recovery<sup>42,108</sup>. There is evidence from meta-analyses suggesting that ECPR may offer superior neurologically intact survival compared with conventional CPR in well-selected populations<sup>54</sup>. These outcomes highlight the importance of selecting patients according to a protocol and activating the ECMO team rapidly.

The following prognostic factors influence the patient treated with ECMO: age; severity of illness indicated by SOFA or SAPS II scores; pre-ECMO lactate levels; duration of mechanical ventilation before ECMO; and timing of ECMO initiation<sup>39,54,109</sup>. Higher survival rates correlate with early cannulation and ECMO initiation, a reversible etiology, and a low pre-ECMO lactate level. Conversely, prolonged pre-ECMO mechanical ventilation (>7 days) and severe comorbidities predict poor outcomes<sup>39</sup>. Despite the advances in technology and management, ECMO remains a high-risk, life-saving therapy. When applied early and under strict selection criteria in experienced centers, survival

rates can reach 60% for respiratory failure and 40%-45% for cardiogenic shock. Nevertheless, a successful outcome depends on expertise, infrastructure, and post-ECMO rehabilitation. According to long-term follow-up studies, a structured neurologic, pulmonary, and psychological evaluation after ECMO is essential to optimizing quality of life among survivors<sup>110,111</sup>.

### Long-Term Outcomes

Even though ECMO can be life-saving in cases of refractory cardiac or respiratory failure, functional recovery among survivors varies<sup>38</sup>. Long-term outcomes depend on survival to hospital discharge and the quality of neurological, physical, and psychological recovery<sup>45,106,109</sup>. Approximately 30-50% of ECMO survivors sustain various degrees of neurological impairment, including memory loss, executive dysfunction, attention deficits, and delayed processing speed<sup>61,62,112</sup>. Such complications are often associated with hypoxic-ischemic injury, microemboli, and intracranial hemorrhage, possibly occurring during extracorporeal support<sup>65</sup>. Post-ECMO cognitive impairment is similar to post-intensive care syndrome (PICS), which underlines the importance of early neurorehabilitation and cognitive screening<sup>113</sup>.

Prolonged ECMO treatment is often followed by physical decline, muscle weakness, and exercise intolerance, primarily due to immobility, steroid exposure, and critical illness myopathy<sup>114,115</sup>. Different studies have shown that early mobilization protocols and multidisciplinary rehabilitation programs improve functional abilities and quality of life<sup>116,117</sup>. Approximately half of VA ECMO survivors experience excellent long-term functional outcomes<sup>118</sup>.

Neuropsychiatric symptoms, neurocognitive and functional impairments have been observed in a considerable number of ECMO patients during long-term follow-up. Survivors are affected by anxiety, depression, and post-traumatic stress disorder (PTSD) in 30-40% of cases<sup>119</sup>. The use of ECMO is associated with substantial psychiatric disorders in patient families<sup>120</sup>. Patients treated with ECMO are significantly associated with a modestly increased risk of a new mental health or social problem diagnosis after discharge compared to non ECMO ICU survived patients<sup>121</sup>. Patients describe memories of the ICU environment that are so intense they resemble nightmares and cause emotional distress. These symptoms resemble those observed in other critically ill populations, but they may be intensified by the invasive and prolonged nature of ECMO therapy<sup>122</sup>. Psychological support and long-term post discharge

follow-up are essential for improving the quality of life of ECMO survivors<sup>38, 123</sup>.

Prognostic factors strongly correlate with both short and long-term outcomes<sup>31</sup>. Predictors of a favorable outcome include younger age (under 60 years), short pre-ECMO duration of mechanical ventilation, early initiation of ECMO especially in cases of cardiogenic shock, low lactate levels at cannulation, absence of multiorgan failure, and reversible primary pathology<sup>31, 54</sup>. On the other hand, delayed ECMO initiation, prolonged CPR, and severe comorbidities have been associated with poor neurological and functional outcomes<sup>45</sup>. Clinical tools such as the RESP, SAVE, and PRESERVE scores can help clinicians estimate prognosis and inform families<sup>54, 107</sup>.

The survival and long-term outcomes of patients are significantly influenced by institutional expertise and the volume of cases at ECMO centers<sup>124</sup>. High-volume centers have lower mortality rates, fewer complications, and better functional recovery after ECMO treatment<sup>27, 125</sup>. This evidence supports centralizing ECMO programs in specialized referral centers to ensure access to multidisciplinary teams skilled in-patient selection, management, and post-ECMO rehabilitation<sup>126</sup>. In conclusion, survival with ECMO treatment is only the first step toward recovery. Survivors often encounter long-term neurological, physical, and psychological challenges<sup>110, 127</sup>. Therefore, a structured post-ECMO follow-up that integrates rehabilitation, neuropsychological assessment, and psychosocial support is crucial<sup>123</sup>. As technology and clinical experience evolve, the focus must shift from survival to quality of life.

### **Cost, Logistics, and Resource Allocation**

Treating a patient with ECMO is a highly resource-intensive therapy that requires advanced technology, continuous specialized care, and substantial institutional infrastructure and expertise<sup>32</sup>. Its clinical efficacy is well established<sup>21</sup> but, the economic and logistical burden remains a major limitation, especially in low- and middle-income countries<sup>128-132</sup>. The substantial cost of ECMO comprises initial setup, consumables, ICU care, and ongoing therapy-related interventions<sup>133</sup>. Depending on factors such as the duration of support, complications, and ancillary treatments, the total hospital cost per patient costs varies widely between indications<sup>130, 131</sup>. Analyses of cost-effectiveness suggest that ECMO may be justifiable for select populations, such as young patients with severe ARDS or reversible cardiogenic shock<sup>134</sup>. However, it is generally resource-intensive when viewed from a population health perspective<sup>135</sup>.

Managing ECMO requires specialized personnel, including critical care physicians, perfusionists, ECMO-trained nurses, and respiratory technicians. These specialists are supported by a multidisciplinary team consisting of cardiologists, infectious disease specialists, nephrologists, surgeons, and physiotherapists<sup>136-138</sup>. There is evidence that centers with dedicated ECMO teams and structured training programs have lower complication rates and have reported better outcomes<sup>125-139</sup>. Maintaining high standards of care requires simulation-based training, standardized protocols, and quality-monitoring programs, especially in new programs or centers that are introducing ECMO for the first time<sup>49, 140, 141</sup>. Centralized ECMO programs and high-volume centers enable efficient care and resource allocation while ensuring patient safety<sup>125</sup>. Several western countries have successfully implemented mobile ECMO units or coordinated referral systems (UMAC), enabling safe inter-hospital transport, timely initiation of therapy, and equitable access for geographically dispersed populations<sup>126, 142, 143</sup>. Requirements for infrastructure include ICU beds equipped for ECMO, bedside monitoring systems, backup power supplies, and access to rapid imaging, laboratory, and surgical support. Low- and middle-income countries face challenges in replicating this infrastructure, which underscores the importance of strategic national planning and phased implementation<sup>17</sup>.

The high costs and limited availability of ECMO raise ethical questions about the allocation of resources<sup>41, 51</sup>. ECMO should be prioritized for patients with a high probability of recovery. Transparent national policies and multidisciplinary decision-making are critical to ensuring equitable use<sup>46, 144</sup>. During pandemics, resource scarcity may necessitate triage protocols, further emphasizing the importance of centralized, protocol-driven ECMO programs<sup>145</sup>.

### **The Challenge in Emerging Health Systems: The Case of Kosova**

Implementing ECMO in emerging health systems, such as in Kosova, presents a series of clinical, logistical, and economic challenges, but should be considered seriously. Key obstacles include the absence of a dedicated ECMO center, limited numbers of trained personnel, underdeveloped technical infrastructure, an unestablished referral network, the absence of a national reimbursement scheme, limited ICU capacity, and potential supply chain constraints.

Despite these challenges, the cost of ECMO per patient may not be prohibitive if the therapy is restricted to young patients with potentially reversible conditions, and if care

is centralized at one or two specialized centers<sup>49</sup>. The careful use of limited resources makes sure that ECMO is both effective for patients and economically feasible, even when resources are limited<sup>27</sup>.

Capacity building and international collaboration are essential to overcome training and infrastructure gaps<sup>146</sup>. These programs can facilitate training abroad for local clinicians or visiting expert teams, as well as equipment sharing or donations. They can also provide tele-mentoring and remote supervision and offer simulation-based education to improve staff performance<sup>17,147</sup>. A phased implementation strategy is recommended, beginning with pilot ECMO programs and robust outcome monitoring. This approach enables local teams to gain experience while ensuring patient safety and optimizing resource allocation.

Multiple contextual factors justify the introduction of ECMO in Kosovo: a young population with a high incidence of trauma and reversible cardiac or respiratory failure; specialized personnel abroad including Kosovar clinicians trained in Western Europe; strong diaspora networks; and international partnerships willing to support training and equipment acquisition. Additionally, local ICU teams are highly motivated to develop ECMO expertise. The use of ECMO would be particularly valuable in select high-impact clinical scenarios, including: fulminant myocarditis in young adults; peripartum cardiomyopathy; refractory ARDS in otherwise healthy patients; severe hypothermia or drug intoxication<sup>88,148</sup>.

A pragmatic approach for integrating ECMO involves several key steps: designating one or two pilot ECMO centers (ideally in Pristina and at one regional hospital); training core ECMO teams abroad or via international experts; acquiring one or two portable ECMO consoles (e.g., CardioHelp™) and initial consumables; developing national protocols and patient selection criteria; implementing simulation-based training and standard operating procedures; and establishing a national ECMO registry to monitor outcomes and guide policy. Evidence from other emerging nations suggests that low-volume programs can succeed with judicious patient selection and centralized care<sup>149</sup>.

### Conclusion and Recommendations

ECMO is a transformative, life saving technology that serves as a short term replacement for the cardiac or respiratory functions of patients with severe, yet potentially recoverable failure. Technological advances, evidence-based protocols, and multicenter collaborations over the past few decades have improved overall survival rates, especially for

patients with ARDS, cardiogenic shock, fulminant myocarditis, peripartum cardiomyopathy, and refractory hypothermia. Despite its clinical benefits, ECMO is complex and resource-intensive. It is also associated with high complication rates. Effective implementation requires centralized, high-volume centers; skilled, multidisciplinary teams; robust patient selection criteria; continuous monitoring; and adherence to standardized protocols. Ethical considerations, including patient selection, equitable allocation of resources, and end-of-life decision-making, must be integrated into clinical practice. When applied judiciously, ECMO can be a lifesaving option for patients with reversible organ failure, even in settings with limited resources. The success depends on careful planning, international collaboration, local expertise, and continuous evaluation of outcomes. As the global experience with ECMO has shown, low-volume programs can be effective when patient selection is strict, care is centralized, and protocols are standardized. In summary, implementing ECMO in Kosovo is feasible, ethically justified, and potentially transformative. This can be achieved through strategic, stepwise planning combined with international support, training, and outcome monitoring. Focusing on high-impact, reversible conditions and leveraging centralized expertise can make ECMO a sustainable, life-saving modality within the Kosovar healthcare system.

### References:

1. Wheeler CR, Bullock KJ. Extracorporeal Membrane Oxygenation. *Respir Care*. 2023;68(8):1158-70.
2. Wrisinger WC, Thompson SL. Basics of Extracorporeal Membrane Oxygenation. *Surg Clin North Am*. 2022;102(1):23-35.
3. Chaves RCF, Rabello Filho R, Timenetsky KT, Moreira FT, Vilanova L, Bravim BA, et al. Extracorporeal membrane oxygenation: a literature review. *Rev Bras Ter Intensiva*. 2019;31(3):410-24.
4. Makdisi G, Wang IW. Extra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technology. *J Thorac Dis*. 2015;7(7):E166-76.
5. Hill JD, O'Brien TG, Murray JJ, Dontigny L, Bramson ML, Osborn JJ, et al. Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). Use of the Bramson membrane lung. *N Engl J Med*. 1972;286(12):629-34.
6. Bartlett RH, Gazzaniga AB, Fong SW, Jefferies MR, Roohk HV, Haiduc N. Extracorporeal membrane oxygenator support for cardiopulmonary failure. Experience in 28 cases. *J Thorac Cardiovasc Surg*. 1977;73(3):375-86.
7. Geetha S, 3rd, Verma N, Chakole V. A Comprehensive Review of Extra Corporeal Membrane Oxygenation: The Lifeline in Critical Moments. *Cureus*. 2024;16(1):e53275.

8. Tonna JE, Abrams D, Brodie D, Greenwood JC, Rubio Mateo-Sidron JA, Usman A, et al. Management of Adult Patients Supported with Venovenous Extracorporeal Membrane Oxygenation (VV ECMO): Guideline from the Extracorporeal Life Support Organization (ELSO). *ASAIO J.* 2021;67(6):601-10.
9. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *Lancet.* 2009;374(9698):1351-63.
10. Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. *N Engl J Med.* 2018;378(21):1965-75.
11. Lorusso R, Meani P, Raffa GM, Kowalewski M. Extracorporeal membrane oxygenation and left ventricular unloading: What is the evidence? *JTCVS Tech.* 2022;13:101-14.
12. Yannopoulos D, Bartos J, Raveendran G, Walser E, Connett J, Murray TA, et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. *Lancet.* 2020;396(10265):1807-16.
13. Meuwese CL, Ramjankhan FZ, Braithwaite SA, de Jonge N, de Jong M, Buijsrogge MP, et al. Extracorporeal life support in cardiogenic shock: indications and management in current practice. *Neth Heart J.* 2018;26(2):58-66.
14. Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. *Crit Care Resusc.* 2013;15(3):172-8.
15. Richardson ASC, Tonna JE, Nanjaya V, Nixon P, Abrams DC, Raman L, et al. Extracorporeal Cardiopulmonary Resuscitation in Adults. Interim Guideline Consensus Statement From the Extracorporeal Life Support Organization. *ASAIO J.* 2021;67(3):221-8.
16. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. *Lancet Respir Med.* 2020;8(5):518-26.
17. Assy J, Skouri H, Charafeddine L, Majdalani M, Younes K, Bulbul Z, et al. Establishing an ECMO program in a developing country: challenges and lessons learned. *Perfusion.* 2019;34(6):508-15.
18. Bertini P, Sangalli F, Meani P, Marabotti A, Rubino A, Scolletta S, et al. Establishing an Extracorporeal Cardiopulmonary Resuscitation Program. *Medicina (Kaunas).* 2024;60(12).
19. Brodie D, Slutsky AS, Combes A. Extracorporeal Life Support for Adults With Respiratory Failure and Related Indications: A Review. *JAMA.* 2019;322(6):557-68.
20. Munshi L, Walkey A, Goligher E, Pham T, Uleryk EM, Fan E. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. *Lancet Respir Med.* 2019;7(2):163-72.
21. Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. *Lancet.* 2020;396(10257):1071-8.
22. Ramanathan K, Shekar K, Ling RR, Barbaro RP, Wong SN, Tan CS, et al. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. *Crit Care.* 2021;25(1):211.
23. Keebler ME, Haddad EV, Choi CW, McGrane S, Zalawadiya S, Schlendorf KH, et al. Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock. *JACC Heart Fail.* 2018;6(6):503-16.
24. Supady A, Belohlavek J, Combes A, Hutin A, Lorusso R, MacLaren G, et al. Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest. *Lancet Respir Med.* 2025;13(9):843-56.
25. Kowalewski M, Zielinski K, Brodie D, MacLaren G, Whitman G, Raffa GM, et al. Venoarterial Extracorporeal Membrane Oxygenation for Postcardiotomy Shock-Analysis of the Extracorporeal Life Support Organization Registry. *Crit Care Med.* 2021;49(7):1107-17.
26. Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. *Crit Care.* 2016;20(1):387.
27. Lebreton G, Schmidt M, Ponnaiah M, Folliguet T, Para M, Guihaire J, et al. Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. *Lancet Respir Med.* 2021;9(8):851-62.
28. Le Gall A, Follin A, Cholley B, Mantz J, Aissaoui N, Pirracchio R. Veno-arterial-ECMO in the intensive care unit: From technical aspects to clinical practice. *Anaesth Crit Care Pain Med.* 2018;37(3):259-68.
29. Schrage B, Burkhoff D, Rubsamen N, Becher PM, Schwarzl M, Bernhardt A, et al. Unloading of the Left Ventricle During Venoarterial Extracorporeal Membrane Oxygenation Therapy in Cardiogenic Shock. *JACC Heart Fail.* 2018;6(12):1035-43.
30. Donker DW, Brodie D, Henriques JPS, Broome M. Left Ventricular Unloading During Veno-Arterial ECMO: A Simulation Study. *ASAIO J.* 2019;65(1):11-20.
31. Lorusso R, Shekar K, MacLaren G, Schmidt M, Pellegrino V, Meyns B, et al. ELSO Interim Guidelines for Venoarterial Extracorporeal Membrane Oxygenation in Adult Cardiac Patients. *ASAIO J.* 2021;67(8):827-44.
32. Brodie D, Abrams D, MacLaren G, Brown CE, Evans L, Barbaro RP, et al. Extracorporeal Membrane Oxygenation during Respiratory Pandemics: Past, Present, and Future. *Am J Respir Crit Care Med.* 2022;205(12):1382-90.
33. Konstantinides SV, Meyer G, Beccatini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and

management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *Eur Respir J*. 2019;54(3).

34. Kjaergaard B, Kristensen JH, Sindby JE, de Neergaard S, Rasmussen BS. Extracorporeal membrane oxygenation in life-threatening massive pulmonary embolism. *Perfusion*. 2019;34(6):467-74.

35. Grennan KN, Maul TM, Nelson JS. Extracorporeal Life Support for Status Asthmaticus: Early Outcomes in Teens and Young Adults. *ASAIO J*. 2022;68(10):1305-11.

36. Odish MF, Yang J, Cheng G, Yi C, Golts E, Madani M, et al. Treatment of Bronchopleural and Alveolopleural Fistulas in Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation, a Case Series and Literature Review. *Crit Care Explor*. 2021;3(5):e0393.

37. Hoetzenecker K, Donahoe L, Yeung JC, Azad S, Fan E, Ferguson ND, et al. Extracorporeal life support as a bridge to lung transplantation-experience of a high-volume transplant center. *J Thorac Cardiovasc Surg*. 2018;155(3):1316-28 e1.

38. Tramm R, Ilic D, Sheldrake J, Pellegrino V, Hodgson C. Recovery, Risks, and Adverse Health Outcomes in Year 1 After Extracorporeal Membrane Oxygenation. *Am J Crit Care*. 2017;26(4):311-9.

39. Tran A, Fernando SM, Rochweg B, Barbaro RP, Hodgson CL, Munshi L, et al. Prognostic factors associated with mortality among patients receiving venovenous extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. *Lancet Respir Med*. 2023;11(3):235-44.

40. Rao P, Khalpey Z, Smith R, Burkhoff D, Kociol RD. Venoaerterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock and Cardiac Arrest. *Circ Heart Fail*. 2018;11(9):e004905.

41. Ramanathan K. Ethical challenges of adult ECMO. *Indian J Thorac Cardiovasc Surg*. 2021;37(Suppl 2):303-8.

42. Abrams D, MacLaren G, Lorusso R, Price S, Yannopoulos D, Vercaemst L, et al. Extracorporeal cardiopulmonary resuscitation in adults: evidence and implications. *Intensive Care Med*. 2022;48(1):1-15.

43. Holmberg MJ, Granfeldt A, Guerguerian AM, Sandroni C, Hsu CH, Gardner RM, et al. Extracorporeal cardiopulmonary resuscitation for cardiac arrest: An updated systematic review. *Resuscitation*. 2023;182:109665.

44. Ortega-Deballon I, Hornby L, Shemie SD, Bhanji F, Guadagno E. Extracorporeal resuscitation for refractory out-of-hospital cardiac arrest in adults: A systematic review of international practices and outcomes. *Resuscitation*. 2016;101:12-20.

45. Debaty G, Babaz V, Durand M, Gaide-Chevronnay L, Fournel E, Blancher M, et al. Prognostic factors for extracorporeal cardiopulmonary resuscitation recipients following out-of-hospital refractory cardiac arrest. A systematic review and meta-analysis. *Resuscitation*. 2017;112:1-10.

46. Enumah ZO, Carrese J, Choi CW. The Ethics of Extracorporeal Membrane Oxygenation: Revisiting the Principles of Clinical Bioethics. *Ann Thorac Surg*. 2021;112(1):61-6.

47. Makdisi T, Makdisi G. Extra corporeal membrane oxygenation support: ethical dilemmas. *Ann Transl Med*. 2017;5(5):112.

48. Badulak J, Rubin J, Moore E, Cunningham M, Ilgen JS, Çoruh B, et al. Development of the Extracorporeal Life Support Organization International Adult Extracorporeal Membrane Oxygenation Curriculum: Creation of Initial Learning Objectives via a Modified Delphi Process. *CHEST Critical Care*. 2023;1(3):100026.

49. Abrams D, Garan AR, Abdelbary A, Bacchetta M, Bartlett RH, Beck J, et al. Position paper for the organization of ECMO programs for cardiac failure in adults. *Intensive Care Med*. 2018;44(6):717-29.

50. Thiagarajan RR, Barbaro RP, Rycus PT, McMullan DM, Conrad SA, Fortenberry JD, et al. Extracorporeal Life Support Organization Registry International Report 2016. *ASAIO J*. 2017;63(1):60-7.

51. Ramanathan K, Cove ME, Caleb MG, Teoh KL, Maclaren G. Ethical dilemmas of adult ECMO: emerging conceptual challenges. *J Cardiothorac Vasc Anesth*. 2015;29(1):229-33.

52. Rajsic S, Trembl B, Jadzic D, Breitkopf R, Oberleitner C, Popovic Krmeta M, et al. Extracorporeal membrane oxygenation for cardiogenic shock: a meta-analysis of mortality and complications. *Ann Intensive Care*. 2022;12(1):93.

53. Lo Coco V, Lorusso R, Raffa GM, Malvindi PG, Pilato M, Martucci G, et al. Clinical complications during veno-arterial extracorporeal membrane oxygenation in post-cardiotomy and non post-cardiotomy shock: still the achille's heel. *J Thorac Dis*. 2018;10(12):6993-7004.

54. Schmidt M, Bailey M, Sheldrake J, Hodgson C, Aubron C, Rycus PT, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. *Am J Respir Crit Care Med*. 2014;189(11):1374-82.

55. Combes A, Slutsky AS, Brodie D. ECMO for Severe Acute Respiratory Distress Syndrome. *N Engl J Med*. 2018;379(11):1091-2.

56. Elmously A, Bobka T, Khin S, Afzal A, de Biasi AR, DeBois WJ, et al. Distal Perfusion Cannulation and Limb Complications in Venoaerterial Extracorporeal Membrane Oxygenation. *J Extra Corpor Technol*. 2018;50(3):155-60.

57. Cevasco M, Takayama H, Ando M, Garan AR, Naka Y, Takeda K. Left ventricular distension and venting strategies for patients on venoaerterial extracorporeal membrane oxygenation. *J Thorac Dis*. 2019;11(4):1676-83.

58. Baldetti L, Gramegna M, Beneduce A, Melillo F, Moroni F, Calvo F, et al. Strategies of left ventricular unloading during VA-ECMO support: a network meta-analysis. *Int J Cardiol*. 2020;312:16-21.

59. Murphy DA, Hockings LE, Andrews RK, Aubron C, Gardiner EE, Pellegrino VA, et al. Extracorporeal membrane oxygenation-hemostatic complications. *Transfus Med Rev*. 2015;29(2):90-101.



60. Olson SR, Murphree CR, Zonies D, Meyer AD, McCarty OJT, Deloughery TG, et al. Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review. *ASAIO J.* 2021;67(3):290-6.
61. Lorusso R, Gelsomino S, Parise O, Di Mauro M, Barili F, Geskes G, et al. Neurologic Injury in Adults Supported With Venovenous Extracorporeal Membrane Oxygenation for Respiratory Failure: Findings From the Extracorporeal Life Support Organization Database. *Crit Care Med.* 2017;45(8):1389-97.
62. Mateen FJ, Muralidharan R, Shinohara RT, Parisi JE, Schears GJ, Wijidicks EF. Neurological injury in adults treated with extracorporeal membrane oxygenation. *Arch Neurol.* 2011;68(12):1543-9.
63. Esper SA, Levy JH, Waters JH, Welsby IJ. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. *Anesth Analg.* 2014;118(4):731-43.
64. Levy JH, Staudinger T, Steiner ME. How to manage anticoagulation during extracorporeal membrane oxygenation. *Intensive Care Med.* 2022;48(8):1076-9.
65. Fletcher-Sandersjoo A, Thelin EP, Bartek J, Jr., Broman M, Salisalmi M, Elmi-Terander A, et al. Incidence, Outcome, and Predictors of Intracranial Hemorrhage in Adult Patients on Extracorporeal Membrane Oxygenation: A Systematic and Narrative Review. *Front Neurol.* 2018;9:548.
66. Cho SM, Hwang J, Chiarini G, Amer M, Antonini MV, Barrett N, et al. Neurological monitoring and management for adult extracorporeal membrane oxygenation patients: Extracorporeal Life Support Organization consensus guidelines. *Crit Care.* 2024;28(1):296.
67. Ostermann M, Lumlertgul N. Acute kidney injury in ECMO patients. *Crit Care.* 2021;25(1):313.
68. Pena-Lopez Y, Machado MC, Rello J. Infection in ECMO patients: Changes in epidemiology, diagnosis and prevention. *Anaesth Crit Care Pain Med.* 2024;43(1):101319.
69. Abrams D, Grasselli G, Schmidt M, Mueller T, Brodie D. ECLS-associated infections in adults: what we know and what we don't yet know. *Intensive Care Med.* 2020;46(2):182-91.
70. Grasselli G, Scaravilli V, Di Bella S, Biffi S, Bombino M, Patroniti N, et al. Nosocomial Infections During Extracorporeal Membrane Oxygenation: Incidence, Etiology, and Impact on Patients' Outcome. *Crit Care Med.* 2017;45(10):1726-33.
71. Ait Hssain A, Vahedian-Azimi A, Ibrahim AS, Hassan IF, Azoulay E, Darmon M. Incidence, risk factors and outcomes of nosocomial infection in adult patients supported by extracorporeal membrane oxygenation: a systematic review and meta-analysis. *Crit Care.* 2024;28(1):158.
72. Lesouhaitier M, Belicard F, Tadie JM. Cardiopulmonary bypass and VA-ECMO induced immune dysfunction: common features and differences, a narrative review. *Crit Care.* 2024;28(1):300.
73. Torre DE, Pirri C. Harlequin Syndrome in Venous Arterial ECMO and ECPELLA: When ECMO and Native or Impella Circulations Collide - A Comprehensive Review. *Rev Cardiovasc Med.* 2025;26(8):39992.
74. Teijeiro-Paradis R, Gannon WD, Fan E. Complications Associated With Venovenous Extracorporeal Membrane Oxygenation-What Can Go Wrong? *Crit Care Med.* 2022;50(12):1809-18.
75. Jones-Akhtarekhavari J, Tribble TA, Zwischenberger JB. Developing an Extracorporeal Membrane Oxygenation Program. *Crit Care Clin.* 2017;33(4):767-75.
76. Schwartz G, Huff EA, van Zyl JS, da Graca B, Gonzalez-Stawinski GV, Velazco J, et al. A system-wide extracorporeal membrane oxygenation quality collaborative improves patient outcomes. *J Thorac Cardiovasc Surg.* 2022;163(4):1366-74 e9.
77. Lorusso R, Centofanti P, Gelsomino S, Barili F, Di Mauro M, Orlando P, et al. Venous Arterial Extracorporeal Membrane Oxygenation for Acute Fulminant Myocarditis in Adult Patients: A 5-Year Multi-Institutional Experience. *Ann Thorac Surg.* 2016;101(3):919-26.
78. Ueda T, Amiya E, Hatano M, Inoue K, Ishida J, Minatsuki S, et al. Prognostic Factors Associated With Early Recovery From Venous Arterial Extracorporeal Membrane Oxygenation Support in Patients With Fulminant Myocarditis. *J Am Heart Assoc.* 2025;14(12):e039673.
79. Vishram-Nielsen JKK, Foroutan F, Rizwan S, Peck SS, Bodack J, Orchanian-Cheff A, et al. Patients with fulminant myocarditis supported with venous-arterial extracorporeal membrane oxygenation: a systematic review and meta-analysis of short-term mortality and impact of risk factors. *Heart Fail Rev.* 2023;28(2):347-57.
80. Nunez JI, Grandin EW, Reyes-Castro T, Sabe M, Quintero P, Motiwala S, et al. Outcomes With Peripheral Venous Arterial Extracorporeal Membrane Oxygenation for Suspected Acute Myocarditis: 10-Year Experience From the Extracorporeal Life Support Organization Registry. *Circ Heart Fail.* 2023;16(7):e010152.
81. Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, et al. Clinical outcomes in fulminant myocarditis requiring extracorporeal membrane oxygenation: a weighted meta-analysis of 170 patients. *J Card Fail.* 2014;20(6):400-6.
82. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2020;75(2):207-21.
83. Hrymak CS, Labib A, Akkanti B, Antonini MV, Bruggeman B, Griffiee MJ, et al. ECMO for the pregnant and peripartum patient: A practical review of indications, unique management considerations, and an approach framework. *Perfusion.* 2025;2676591251321070.
84. Naoum E, Ortoleva J. Peripartum extracorporeal life support. *BJA Educ.* 2024;24(9):335-42.
85. Olson TL, O'Neil ER, Ramanathan K, Lorusso R, MacLaren G, Anders MM. Extracorporeal membrane oxygenation in peripartum cardiomyopathy: A review of the ELSO Registry. *Int J Cardiol.* 2020;311:71-6.

86. Swol J, Darocha T, Paal P, Brugger H, Podsiadlo P, Kosinski S, et al. Extracorporeal Life Support in Accidental Hypothermia with Cardiac Arrest-A Narrative Review. *ASAIO J.* 2022;68(2):153-62.
87. Farstad M, Andersen KS, Koller ME, Grong K, Segadal L, Husby P. Rewarming from accidental hypothermia by extracorporeal circulation. A retrospective study. *Eur J Cardiothorac Surg.* 2001;20(1):58-64.
88. Ledoux A, Saint Leger P. Therapeutic management of severe hypothermia with veno-arterial ECMO: where do we stand? Case report and review of the current literature. *Scand J Trauma Resusc Emerg Med.* 2020;28(1):30.
89. Boey JJE, Dhundi U, Ling RR, Chiew JK, Fong NC, Chen Y, et al. Extracorporeal Membrane Oxygenation for Pulmonary Embolism: A Systematic Review and Meta-Analysis. *J Clin Med.* 2023;13(1).
90. Meneveau N, Guillon B, Planquette B, Piton G, Kimmoun A, Gaide-Chevronnay L, et al. Outcomes after extracorporeal membrane oxygenation for the treatment of high-risk pulmonary embolism: a multicentre series of 52 cases. *Eur Heart J.* 2018;39(47):4196-204.
91. Abdulaziz SM, Kakar V, Kumar PG, Hassan IF, Combes A, Brodie D, et al. Mechanical Circulatory Support for Massive Pulmonary Embolism. *J Am Heart Assoc.* 2025;14(1):e036101.
92. Daubin C, Lehoux P, Ivascau C, Tasle M, Bousta M, Lepage O, et al. Extracorporeal life support in severe drug intoxication: a retrospective cohort study of seventeen cases. *Crit Care.* 2009;13(4):R138.
93. Bouchard J, Shepherd G, Hoffman RS, Gosselin S, Roberts DM, Li Y, et al. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. *Crit Care.* 2021;25(1):201.
94. Wang GS, Levitan R, Wiegand TJ, Lowry J, Schult RF, Yin S, et al. Extracorporeal Membrane Oxygenation (ECMO) for Severe Toxicological Exposures: Review of the Toxicology Investigators Consortium (ToxIC). *J Med Toxicol.* 2016;12(1):95-9.
95. Oda Y, Yamasaki H, Osawa T, Igarashi M, Ishizu T. Rescuing Protamine Anaphylaxis Refractory to Adrenaline Using Extracorporeal Membrane Oxygenation. *JACC Case Rep.* 2025;30(6 Pt 1):102966.
96. Joseph J, Bellezzo J. Refractory Anaphylactic Shock Requiring Emergent Venous Arterial Extracorporeal Membrane Oxygenation in the Emergency Department: A Case Report. *J Emerg Nurs.* 2022;48(6):626-30.
97. Barbaro RP, MacLaren G, Boonstra PS, Combes A, Agerstrand C, Annich G, et al. Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry. *Lancet.* 2021;398(10307):1230-8.
98. Schmidt M, Hajage D, Lebreton G, Monsel A, Voiriot G, Levy D, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. *Lancet Respir Med.* 2020;8(11):1121-31.
99. Broman LM, Dubrovskaja O, Balik M. Extracorporeal Membrane Oxygenation for Septic Shock in Adults and Children: A Narrative Review. *J Clin Med.* 2023;12(20).
100. Bréchet N, Hajage D, Kimmoun A, Demiselle J, Agerstrand C, Montero S, et al. Venous arterial extracorporeal membrane oxygenation to rescue sepsis-induced cardiogenic shock: a retrospective, multicentre, international cohort study. *The Lancet.* 2020;396(10250):545-52.
101. Zhang H, Xu Y, Huang X, Yang S, Li R, Wu Y, et al. Extracorporeal membrane oxygenation in adult patients with sepsis and septic shock: Why, how, when, and for whom. *J Intensive Med.* 2024;4(1):62-72.
102. Kim JH, Pieri M, Landoni G, Scandroglia AM, Calabro MG, Fominskiy E, et al. Venovenous ECMO treatment, outcomes, and complications in adults according to large case series: A systematic review. *Int J Artif Organs.* 2021;44(7):481-8.
103. Low CJW, Ramanathan K, Ling RR, Ho MJC, Chen Y, Lorusso R, et al. Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with cardiac arrest: a comparative meta-analysis and trial sequential analysis. *Lancet Respir Med.* 2023;11(10):883-93.
104. Magnet I, Behringer W, Eibensteiner F, Ettl F, Grafeneder J, Heinz G, et al. Extracorporeal Cardiopulmonary Resuscitation: Outcomes Improve With Center Experience. *Ann Emerg Med.* 2025;85(5):421-7.
105. Wang L, Wang K, Wang Y, Yang F, Li C, Hao X, et al. A simple VA-ECMO bundle in adult patients with cardiogenic shock: an analysis of ELSO registry. *EClinicalMedicine.* 2025;87:103423.
106. Serpa Neto A, Higgins AM, Bailey MJ, Anderson S, Bernard S, Fulcher BJ, et al. Long-Term Functional Outcomes in the First 12 Months After VA-ECMO in Adult Patients: A Prospective, Multicenter Study. *Circ Heart Fail.* 2025;18(6):e012476.
107. Burrell AJ, Pellegrino VA, Wolfe R, Wong WK, Cooper DJ, Kaye DM, et al. Long-term survival of adults with cardiogenic shock after venous arterial extracorporeal membrane oxygenation. *J Crit Care.* 2015;30(5):949-56.
108. Leroux L, Dennis-Benford NB, Bergeron A, Lamhaut L, Cournoyer A, Grunau B, et al. Impact of prehospital extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest on survival with good neurological function: a systematic review and meta-analysis. *Resusc Plus.* 2025;24:100974.
109. Rozencwajg S, Pilcher D, Combes A, Schmidt M. Outcomes and survival prediction models for severe adult acute respiratory distress syndrome treated with extracorporeal membrane oxygenation. *Crit Care.* 2016;20(1):392.
110. Hodgson CL, Hayes K, Everard T, Nichol A, Davies AR, Bailey MJ, et al. Long-term quality of life in patients with acute respiratory distress syndrome requiring extracorporeal membrane oxygenation for refractory hypoxaemia. *Crit Care.* 2012;16(5):R202.
111. Rilinger J, Krotzsch K, Bemtgen X, Jackel M, Zotzmann V,

- Lang CN, et al. Long-term survival and health-related quality of life in patients with severe acute respiratory distress syndrome and veno-venous extracorporeal membrane oxygenation support. *Crit Care*. 2021;25(1):410.
112. Palakshappa JA, Krall JTW, Belfield LT, Files DC. Long-Term Outcomes in Acute Respiratory Distress Syndrome: Epidemiology, Mechanisms, and Patient Evaluation. *Crit Care Clin*. 2021;37(4):895-911.
113. Hiser SL, Fatima A, Ali M, Needham DM. Post-intensive care syndrome (PICS): recent updates. *J Intensive Care*. 2023;11(1):23.
114. Chen X, Lei X, Xu X, Zhou Y, Huang M. Intensive Care Unit-Acquired Weakness in Patients With Extracorporeal Membrane Oxygenation Support: Frequency and Clinical Characteristics. *Front Med (Lausanne)*. 2022;9:792201.
115. Hayes K, Holland AE, Pellegrino VA, Mathur S, Hodgson CL. Acute skeletal muscle wasting and relation to physical function in patients requiring extracorporeal membrane oxygenation (ECMO). *J Crit Care*. 2018;48:1-8.
116. Abrams D, Madahar P, Eckhardt CM, Short B, Yip NH, Parekh M, et al. Early Mobilization during Extracorporeal Membrane Oxygenation for Cardiopulmonary Failure in Adults: Factors Associated with Intensity of Treatment. *Ann Am Thorac Soc*. 2022;19(1):90-8.
117. Abrams D, Javidfar J, Farrand E, Mongero LB, Agerstrand CL, Ryan P, et al. Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study. *Crit Care*. 2014;18(1):R38.
118. Ortuno S, Bachelet D, Varnet O, Tridon C, de Montmollin E, Dessajan J, et al. Long-Term Functional and Quality-of-Life Outcomes in Survivors of Refractory Cardiogenic Shock Treated With Venous-arterial Extracorporeal Membrane Oxygenation. *Crit Care Explor*. 2025;7(12):e1359.
119. Khan IR, Saulle M, Oldham MA, Weber MT, Schifitto G, Lee HB. Cognitive, Psychiatric, and Quality of Life Outcomes in Adult Survivors of Extracorporeal Membrane Oxygenation Therapy: A Scoping Review of the Literature. *Crit Care Med*. 2020;48(10):e959-e70.
120. Demory A, Broden E, Equey L, Funaro MC, Sharifi M, Harpaz-Rotem I, et al. Trauma-related psychopathologies after extracorporeal membrane oxygenation support: A systematic review and meta-analysis. *Perfusion*. 2025;40(7):1546-58.
121. Fernando SM, Scott M, Talarico R, Fan E, McIsaac DI, Sood MM, et al. Association of Extracorporeal Membrane Oxygenation With New Mental Health Diagnoses in Adult Survivors of Critical Illness. *JAMA*. 2022;328(18):1827-36.
122. Wilcox ME, Jaramillo-Rocha V, Hodgson C, Taglione MS, Ferguson ND, Fan E. Long-Term Quality of Life After Extracorporeal Membrane Oxygenation in ARDS Survivors: Systematic Review and Meta-Analysis. *J Intensive Care Med*. 2020;35(3):233-43.
123. Rossong H, Debreuil S, Yan W, Hiebert BM, Singal RK, Arora RC, et al. Long-term survival and quality of life after extracorporeal membrane oxygenation. *J Thorac Cardiovasc Surg*. 2023;166(2):555-66 e2.
124. Verma A, Hadaya J, Williamson C, Kronen E, Sakowitz S, Bakhtiyar SS, et al. A contemporary analysis of the volume-outcome relationship for extracorporeal membrane oxygenation in the United States. *Surgery*. 2023;173(6):1405-10.
125. Barbaro RP, Odetola FO, Kidwell KM, Paden ML, Bartlett RH, Davis MM, et al. Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. *Am J Respir Crit Care Med*. 2015;191(8):894-901.
126. Rabie AA, Elhazmi A, Azzam MH, Abdelbary A, Labib A, Combes A, et al. Expert consensus statement on venovenous extracorporeal membrane oxygenation ECMO for COVID-19 severe ARDS: an international Delphi study. *Ann Intensive Care*. 2023;13(1):36.
127. Stadlbauer A, Philipp A, Blecha S, Lubnow M, Lunz D, Li J, et al. Long-term follow-up and quality of life in patients receiving extracorporeal membrane oxygenation for pulmonary embolism and cardiogenic shock. *Ann Intensive Care*. 2021;11(1):181.
128. Alenazi A, Alotaibi B, Madan J, Yeung J, Johnson S, Couper K. The cost-effectiveness of extracorporeal cardiopulmonary resuscitation (ECPR) for refractory cardiac arrest: A systematic review. *Resuscitation*. 2025;216:110822.
129. Spoelstra-de Man AME, Smit B, Oudemans-van Straaten HM, Smulders YM. Cardiovascular effects of hyperoxia during and after cardiac surgery. *Anaesthesia*. 2015;70(11):1307-19.
130. Oude Lansink-Hartgring A, Miranda DDR, Mandigers L, Delnoij T, Lorusso R, Maas JJ, et al. Health-related quality of life, one-year costs and economic evaluation in extracorporeal membrane oxygenation in critically ill adults. *J Crit Care*. 2023;73:154215.
131. Oude Lansink-Hartgring A, van Minnen O, Vermeulen KM, van den Bergh WM, Dutch Extracorporeal Life Support Study G. Hospital Costs of Extracorporeal Membrane Oxygenation in Adults: A Systematic Review. *Pharmacoecon Open*. 2021;5(4):613-23.
132. Dennis M, Zmudzki F, Burns B, Scott S, Gattas D, Reynolds C, et al. Cost effectiveness and quality of life analysis of extracorporeal cardiopulmonary resuscitation (ECPR) for refractory cardiac arrest. *Resuscitation*. 2019;139:49-56.
133. Papanikolaou V, Goh E, Carrandi A, Charles-Nelson A, Kottakkal K, Romero L, et al. Health Resource Utilization and Outcomes Among Patients Who Receive Extracorporeal Membrane Oxygenation. *CJC Open*. 2025;7(6):750-8.
134. Jaamaa-Holmberg S, Salmela B, Suojäranta R, Lemström KB, Lommi J. Cost-utility of venous-arterial extracorporeal membrane oxygenation in cardiogenic shock and cardiac arrest. *Eur Heart J Acute Cardiovasc Care*. 2020;9(4):333-41.
135. Lazar HL. Commentary: Extracorporeal membrane

oxygenation: Is it life-saving and cost effective for all patients? *JTCVS Open*. 2020;1:73-5.

136. Hickey S, Ortiz C, Chen WT, Black PJ, Grogan T, Benharash P, et al. Implementation of a Multidisciplinary Team for Initiation of Extracorporeal Cardiopulmonary Resuscitation in Patients Presenting After Out-of-hospital Cardiac Arrest. *J Cardiothorac Vasc Anesth*. 2025;39(5):1236-41.

137. Hong D, Choi KH, Cho YH, Cho SH, Park SJ, Kim D, et al. Multidisciplinary team approach in acute myocardial infarction patients undergoing veno-arterial extracorporeal membrane oxygenation. *Ann Intensive Care*. 2020;10(1):83.

138. Na SJ, Chung CR, Choi HJ, Cho YH, Sung K, Yang JH, et al. The effect of multidisciplinary extracorporeal membrane oxygenation team on clinical outcomes in patients with severe acute respiratory failure. *Ann Intensive Care*. 2018;8(1):31.

139. Cavarocchi NC. Introduction to Extracorporeal Membrane Oxygenation. *Crit Care Clin*. 2017;33(4):763-6.

140. Broman LM, Dimberger DR, Malfertheiner MV, Aokage T, Morberg P, Naesheim T, et al. International Survey on Extracorporeal Membrane Oxygenation Transport. *ASAIO J*. 2020;66(2):214-25.

141. Sakamoto S. Simulation-based training for handling extracorporeal membrane oxygenation emergencies. *J Thorac Dis*. 2017;9(10):3649-51.

142. Broman LM. Inter-hospital transports on extracorporeal membrane oxygenation in different health-care systems. *J Thorac Dis*. 2017;9(9):3425-9.

143. Nwozuzu A, Fontes ML, Schonberger RB. Mobile Extracorporeal Membrane Oxygenation Teams: The North American Versus the European Experience. *J Cardiothorac Vasc Anesth*. 2016;30(6):1441-8.

144. Connelly Y, Barnea R, Tur-Sinai A, Tal O. Multicultural ethics in crisis: prioritizing ECMO allocation and the role of critical consciousness. *Int J Equity Health*. 2025;24(1):221.

145. Dao B, Savulescu J, Suen JY, Fraser JF, Wilkinson DJC. Ethical factors determining ECMO allocation during the COVID-19 pandemic. *BMC Med Ethics*. 2021;22(1):70.

146. Elkhwad M, More KS, Anand D, Al-Maraghi S, Crowe M, Wong D, et al. Successful Establishment of the First Neonatal Respiratory Extracorporeal Membrane Oxygenation (ECMO) Program in the Middle East, in Collaboration With Pediatric Services. *Front Pediatr*. 2020;8:506.

147. Wong AS, Marwali EM, Maclaren G, Ogino M, Fraser J, Chi Keung PL, et al. ECMO simulation training during a worldwide pandemic: The role of ECMO telesimulation. *Perfusion*. 2023;38(5):1029-36.

148. Ouweneel DM, Schotborgh JV, Limpens J, Sjaauw KD, Engstrom AE, Lagrand WK, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. *Intensive Care Med*. 2016;42(12):1922-34.

149. Joyce CJ, Cook DA, Walsham J, Krishnan A, Lo W, Saamaan J, et al. Low volume ECMO results study. *Crit Care Resusc*. 2020;22(4):327-34.